3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Tuberous Sclerosis
1
Stomach Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Myasthenia Gravis
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Epilepsy
1
Diffuse Intrinsic Pontine Glioma
1
Cut-Off Value
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Endometrioid
1
Breast Neoplasms
1
Breast Cancer Lymphedema
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Interventions
pembrolizumab
180
Gemcitabine
168
Paclitaxel
150
Carboplatin
134
Bevacizumab
126
Cisplatin
113
Docetaxel
112
Cyclophosphamide
109
Exercise
97
Nivolumab
93
Fluorouracil
88
Capecitabine
85
Dexamethasone
81
Irinotecan
74
Radiotherapy
68
Oxaliplatin
68
Pemetrexed
66
Standard of Care
64
Leucovorin
63
Cetuximab
59
Sorafenib
53
Erlotinib Hydrochloride
53
Drug Therapy
53
Blood Specimen Collection
51
Doxorubicin
50
atezolizumab
48
trametinib
47
Ipilimumab
47
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
42
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms
×
Fluid Therapy
×
Clear all
NCT04987463
2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3
Unknown
60 enrolled